T2 Biosystems, Inc. (TTOO) DCF Valuation

T2 Biosystems, Inc. (TTOO) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

T2 Biosystems, Inc. (TTOO) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Whether you’re an investor or analyst, this T2 Biosystems, Inc. (TTOO) DCF Calculator is your go-to resource for accurate valuation. Loaded with real data from T2 Biosystems, Inc., you can adjust forecasts and observe the effects in real-time.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 8.3 18.1 28.1 22.3 7.2 8.4 9.8 11.4 13.3 15.5
Revenue Growth, % 0 117.52 54.76 -20.5 -67.75 16.63 16.63 16.63 16.63 16.63
EBITDA -48.3 -38.5 -41.1 -55.2 -43.9 -8.4 -9.8 -11.4 -13.3 -15.5
EBITDA, % -579.47 -212.28 -146.58 -247.46 -609.97 -100 -100 -100 -100 -100
Depreciation 3.6 3.2 2.5 2.3 .9 1.5 1.8 2.1 2.5 2.9
Depreciation, % 43.7 17.41 9.05 10.18 11.94 18.45 18.45 18.45 18.45 18.45
EBIT -51.9 -41.6 -43.7 -57.5 -44.7 -8.4 -9.8 -11.4 -13.3 -15.5
EBIT, % -623.17 -229.69 -155.62 -257.64 -621.91 -100 -100 -100 -100 -100
Total Cash 11.0 42.2 32.2 10.3 15.7 7.5 8.7 10.2 11.9 13.9
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 2.8 5.1 5.1 2.2 1.4
Account Receivables, % 33.89 28.12 18.3 9.7 19.74
Inventories 3.6 3.6 3.9 4.3 4.8 2.7 3.2 3.7 4.4 5.1
Inventories, % 43.18 20.06 13.93 19.5 67 32.73 32.73 32.73 32.73 32.73
Accounts Payable 3.8 2.1 2.8 1.3 1.5 1.6 1.8 2.1 2.5 2.9
Accounts Payable, % 45.03 11.35 10.09 5.81 21.23 18.7 18.7 18.7 18.7 18.7
Capital Expenditure -.8 -.8 -.5 -.3 -.2 -.3 -.4 -.4 -.5 -.6
Capital Expenditure, % -9.13 -4.43 -1.64 -1.52 -2.67 -3.88 -3.88 -3.88 -3.88 -3.88
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -55.6 -43.8 -47.4 -58.4 -44.7 -8.4 -9.8 -11.4 -13.3 -15.5
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -55.3 -45.4 -44.9 -55.5 -43.6 -5.5 -8.9 -10.3 -12.1 -14.1
WACC, % 10.69 10.69 10.69 10.69 10.69 10.69 10.69 10.69 10.69 10.69
PV UFCF
SUM PV UFCF -36.3
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) -14
Terminal Value -165
Present Terminal Value -99
Enterprise Value -135
Net Debt 34
Equity Value -169
Diluted Shares Outstanding, MM 3
Equity Value Per Share -64.86

What You Will Get

  • Real T2 Biosystems Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for T2 Biosystems, Inc. (TTOO).
  • Full Customization: Adjust all critical parameters (yellow cells) such as WACC, growth %, and tax rates tailored for T2 Biosystems, Inc. (TTOO).
  • Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on T2 Biosystems, Inc. (TTOO)’s fair value.
  • Versatile Excel Template: Designed for quick edits, scenario testing, and detailed projections specific to T2 Biosystems, Inc. (TTOO).
  • Time-Saving and Accurate: Avoid building models from scratch while ensuring precision and flexibility for T2 Biosystems, Inc. (TTOO).

Key Features

  • Comprehensive T2 Biosystems Data: Gain access to precise pre-loaded historical metrics and future forecasts.
  • Adjustable Forecast Parameters: Modify highlighted fields such as WACC, growth rates, and profit margins.
  • Real-Time Calculations: Automatic updates for DCF, Net Present Value (NPV), and cash flow assessments.
  • Interactive Dashboard: User-friendly charts and summaries to help you visualize your valuation insights.
  • Designed for All Skill Levels: An intuitive layout tailored for investors, CFOs, and consultants alike.

How It Works

  • Step 1: Download the prebuilt Excel template featuring T2 Biosystems' data included.
  • Step 2: Review the pre-filled sheets to familiarize yourself with the essential metrics.
  • Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
  • Step 4: Instantly see the recalculated results, including T2 Biosystems' intrinsic value.
  • Step 5: Make informed investment decisions or create reports based on the outputs.

Why Choose This Calculator for T2 Biosystems, Inc. (TTOO)?

  • All-in-One Solution: Features DCF, WACC, and financial ratio analyses tailored for T2 Biosystems, Inc. (TTOO).
  • Flexible Inputs: Modify yellow-highlighted cells to explore different financial scenarios.
  • In-Depth Analysis: Automatically computes T2 Biosystems, Inc. (TTOO)'s intrinsic value and Net Present Value.
  • Preloaded Information: Historical and projected data provide a solid foundation for analysis.
  • High-Quality Standards: Perfect for financial analysts, investors, and business consultants focusing on T2 Biosystems, Inc. (TTOO).

Who Should Use This Product?

  • Biomedical Students: Explore diagnostic technologies and apply your knowledge using real-world data.
  • Researchers: Integrate cutting-edge models into your studies or clinical trials.
  • Healthcare Investors: Validate your investment strategies and evaluate the performance of T2 Biosystems, Inc. (TTOO).
  • Data Analysts: Enhance your analysis with a customizable model tailored for diagnostic innovations.
  • Healthcare Professionals: Understand how emerging companies like T2 Biosystems, Inc. (TTOO) are revolutionizing diagnostics.

What the Template Contains

  • Preloaded TTOO Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
  • DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
  • Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
  • Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
  • Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
  • Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.

No products were found matching.